Literature DB >> 28359770

Evaluation of cell viability dyes in antiviral assays with RNA viruses that exhibit different cytopathogenic properties.

Donald F Smee1, Brett L Hurst2, W Joseph Evans2, Nathan Clyde2, Sean Wright2, Christopher Peterson2, Kie-Hoon Jung2, Craig W Day2.   

Abstract

Studies were conducted to determine the performance of four dyes in assessing antiviral activities of compounds against three RNA viruses with differing cytopathogenic properties. Dyes included alamarBlue® measured by absorbance (ALB-A) and fluorescence (ALB-F), neutral red (NR), Viral ToxGlo™ (VTG), and WST-1. Viruses were chikungunya, dengue type 2, and Junin, which generally cause 100, 80-90, and 50% maximal cytopathic effect (CPE), respectively, in Vero or Vero 76 cells Compounds evaluated were 6-azauridine, BCX-4430, 3-deazaguanine, EICAR, favipiravir, infergen, mycophenolic acid (MPA), ribavirin, and tiazofurin. The 50% virus-inhibitory (EC50) values for each inhibitor and virus combination did not vary significantly based on the dye used. However, dyes varied in distinguishing the vitality of virus-infected cultures when not all cells were killed by virus infection. For example, VTG uptake into dengue-infected cells was nearly 50% when visual examination showed only 10-20% cell survival. ALB-A measured infected cell viability differently than ALB-F as follows: 16% versus 32% (dengue-infected), respectively, and 51% versus 72% (Junin-infected), respectively. Cytotoxicity (CC50) assays with dyes in uninfected proliferating cells produced similar CC50 values for EICAR (1.5-8.9μM) and MPA (0.8-2.5μM). 6-Azauridine toxicity was 6.1-17.5μM with NR, VTG, and WST-1, compared to 48-92μM with ALB-A and ALB-F (P<0.001). Curiously, the CC50 values for 3-deazaguanine were 83-93μM with ALB-F versus 2.4-7.0μM with all other dyes including ALB-A (P<0.001). Overall, ALB minimized the toxicities detected with these two inhibitors. Because the choice of dyes affected CC50 values, this impacted on the resulting in vitro selectivity indexes (calculated as CC50/EC50 ratio).
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antiviral; Chikungunya virus; Dengue virus; Dye assays; Junin virus

Mesh:

Substances:

Year:  2017        PMID: 28359770      PMCID: PMC5479350          DOI: 10.1016/j.jviromet.2017.03.012

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.623


  45 in total

1.  Comparisons of two in vitro cytotoxicity assays-The neutral red (NR) and tetrazolium MTT tests.

Authors:  E Borenfreund; H Babich; N Martin-Alguacil
Journal:  Toxicol In Vitro       Date:  1988       Impact factor: 3.500

2.  Virazole (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide; a cytostatic agent.

Authors:  W E Müller; A Maidhof; H Taschner; R K Zahn
Journal:  Biochem Pharmacol       Date:  1977-06-01       Impact factor: 5.858

3.  Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses.

Authors:  Jean Marc Crance; Natale Scaramozzino; Alain Jouan; Daniel Garin
Journal:  Antiviral Res       Date:  2003-03       Impact factor: 5.970

4.  Interferon alfacon-1 protects hamsters from lethal pichinde virus infection.

Authors:  Brian B Gowen; Dale L Barnard; Donald F Smee; Min-Hui Wong; Anne M Pace; Kie-Hoon Jung; Scott G Winslow; Kevin W Bailey; Lawrence M Blatt; Robert W Sidwell
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

5.  In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination.

Authors:  S Briolant; D Garin; N Scaramozzino; A Jouan; J M Crance
Journal:  Antiviral Res       Date:  2004-02       Impact factor: 5.970

6.  Susceptibilities of enterovirus D68, enterovirus 71, and rhinovirus 87 strains to various antiviral compounds.

Authors:  Donald F Smee; W Joseph Evans; K C Nicolaou; E Bart Tarbet; Craig W Day
Journal:  Antiviral Res       Date:  2016-04-07       Impact factor: 5.970

7.  In vitro antiviral activity of mycophenolic acid and its reversal by guanine-type compounds.

Authors:  J C Cline; J D Nelson; K Gerzon; R H Williams; D C Delong
Journal:  Appl Microbiol       Date:  1969-07

8.  Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models.

Authors:  John D Morrey; Craig W Day; Justin G Julander; Lawrence M Blatt; Donald F Smee; Robert W Sidwell
Journal:  Antivir Chem Chemother       Date:  2004-03

9.  A new assay system for guinea pig interferon biological activity.

Authors:  Toshiko Yamamoto; Amminikutty Jeevan; Kazue Ohishi; Yasuhiro Nojima; Kiyoko Umemori; Saburo Yamamoto; David N McMurray
Journal:  J Interferon Cytokine Res       Date:  2002-07       Impact factor: 2.607

10.  Mycophenolic acid and thiazole adenine dinucleotide inhibition of Tritrichomonas foetus inosine 5'-monophosphate dehydrogenase: implications on enzyme mechanism.

Authors:  L Hedstrom; C C Wang
Journal:  Biochemistry       Date:  1990-01-30       Impact factor: 3.162

View more
  15 in total

1.  Synthesis of d-(+)-camphor-based N-acylhydrazones and their antiviral activity.

Authors:  Kseniya S Kovaleva; Fedor I Zubkov; Nikolay I Bormotov; Roman A Novikov; Pavel V Dorovatovskii; Victor N Khrustalev; Yuriy V Gatilov; Vladimir V Zarubaev; Olga I Yarovaya; Larisa N Shishkina; Nariman F Salakhutdinov
Journal:  Medchemcomm       Date:  2018-10-26       Impact factor: 3.597

2.  Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.

Authors:  Robert L Hoffman; Robert S Kania; Mary A Brothers; Jay F Davies; Rose A Ferre; Ketan S Gajiwala; Mingying He; Robert J Hogan; Kirk Kozminski; Lilian Y Li; Jonathan W Lockner; Jihong Lou; Michelle T Marra; Lennert J Mitchell; Brion W Murray; James A Nieman; Stephen Noell; Simon P Planken; Thomas Rowe; Kevin Ryan; George J Smith; James E Solowiej; Claire M Steppan; Barbara Taggart
Journal:  J Med Chem       Date:  2020-10-15       Impact factor: 7.446

3.  Comparison of three dimensional synergistic analyses of percentage versus logarithmic data in antiviral studies.

Authors:  Donald F Smee; Mark N Prichard
Journal:  Antiviral Res       Date:  2017-07-01       Impact factor: 5.970

4.  In vitro Screening of Antileishmanial Activity of Natural Product Compounds: Determination of IC50, CC50 and SI Values.

Authors:  Olga S Koutsoni; Kalliopi Karampetsou; Eleni Dotsika
Journal:  Bio Protoc       Date:  2019-11-05

5.  AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19.

Authors:  Steven S Good; Jonna Westover; Kie Hoon Jung; Xiao-Jian Zhou; Adel Moussa; Paolo La Colla; Gabriella Collu; Bruno Canard; Jean-Pierre Sommadossi
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

6.  In vitro Assessment of Antiviral Effect of Natural Compounds on Porcine Epidemic Diarrhea Coronavirus.

Authors:  Manuel Gómez-García; Héctor Puente; Héctor Argüello; Óscar Mencía-Ares; Pedro Rubio; Ana Carvajal
Journal:  Front Vet Sci       Date:  2021-03-29

7.  Antiviral screening on Alpinia eremochlamys, Etlingera flexuosa, and Etlingera acanthoides extracts against HIV-infected MT-4 cells.

Authors:  Muhammad Sulaiman Zubair; Siti Qamariyah Khairunisa; Agustinus Widodo; Ramadanil Pitopang
Journal:  Heliyon       Date:  2021-04-08

8.  Drug repurposing against SARS-CoV-1, SARS-CoV-2 and MERS-CoV.

Authors:  Sarah Aherfi; Bruno Pradines; Christian Devaux; Stéphane Honore; Philippe Colson; Bernard La Scola; Didier Raoult
Journal:  Future Microbiol       Date:  2021-11-10       Impact factor: 3.165

9.  Tilorone, a Broad-Spectrum Antiviral for Emerging Viruses.

Authors:  Sean Ekins; Peter B Madrid
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

10.  Activity of Galidesivir in a Hamster Model of SARS-CoV-2.

Authors:  Ray Taylor; Richard Bowen; James F Demarest; Michael DeSpirito; Airn Hartwig; Helle Bielefeldt-Ohmann; Dennis M Walling; Amanda Mathis; Yarlagadda S Babu
Journal:  Viruses       Date:  2021-12-21       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.